Cargando…
Defining eligible patients for allele-selective chemotherapies targeting NAT2 in colorectal cancer
Therapies targeting somatic bystander genetic events represent a new avenue for cancer treatment. We recently identified a subset of colorectal cancer (CRC) patients who are heterozygous for a wild-type and a low activity allele (NAT2*6) but lack the wild-type allele in their tumors due to loss of h...
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7775439/ https://www.ncbi.nlm.nih.gov/pubmed/33384440 http://dx.doi.org/10.1038/s41598-020-80288-z |